Osteomyelitis
Conditions
Keywords
Osteomyelitis, Diabetes, Foot Infection
Brief summary
The Infectious Diseases Society of America (IDSA) 2012 guidelines for the diagnosis and treatment of diabetic foot infections state that for the treatment of diabetic foot osteomyelitis No data support the superiority of any specific antibiotic agent or treatment strategy, route, or duration of therapy. Traditionally, osteomyelitis has been treated with a long course of intravenous antibiotics, generally six weeks. Oral antibiotics with high bioavailability and adequate bone penetration have been shown in published studies to be effective for the treatment of osteomyelitis. The investigators propose to conduct a prospective, single-center, randomized, open trial at Loyola University Medical Center (LUMC) comparing the efficacy of oral antibiotic therapy to intravenous (IV) antibiotic therapy for the treatment of diabetic foot osteomyelitis. The investigators hypothesize that oral antibiotic therapy is equivalent to IV antibiotic therapy. Bone/tissue cultures are obtained for all patients for clinical purposes and are sent to pathology for histologic examination and to the clinical microbiology laboratory for culture and susceptibility. Patients will receive six weeks of IV or oral antibiotic therapy depending upon their randomization group. Primary outcomes at six months clinical follow-up will include: (i) no evidence of bone infection and (ii) resolution of ulcer.
Detailed description
Currently, available literature is not adequate to determine the best agent, route, or duration of antibiotic therapy for the treatment of chronic osteomyelitis. The standard of therapy has been to treat patients with a parenteral antibiotic for four to six weeks. In a recent literature review by Spellberg et al. it was concluded that oral and parenteral antibiotic therapy have similar cure rates for the treatment of chronic osteomyelitis. Oral antibiotic therapy is associated with a lower risk to the patient due to avoiding the need of a central IV line. Additionally, oral therapy costs less than a course of IV antibiotics. Oral antibiotics with high bioavailability and good bone penetration include, fluoroquinolones, linezolid, trimethoprim/sulfamethoxazole (2 tabs bid), clindamycin and metronidazole. These antibiotics have been shown in recent studies to obtain levels in the bone that exceed the minimum inhibitory concentration (MIC) levels of the targeted organisms. According to the IDSA 2012 guidelines for the treatment of diabetic foot infections, the diagnosis of osteomyelitis can be made via plain radiographs or MRI imaging (more sensitive). A bone scan can be considered if an MRI cannot be done. The preferred method of diagnosis is by bone culture and histology. The guidelines also recommend surgical debridement to healthy tissue for diabetic foot infections followed by antibiotic therapy. The Purpose of this study is to compare the efficacy of oral antibiotic therapy with intravenous antibiotic therapy for the treatment of diabetic foot osteomyelitis following surgical debridement. They hypothesis is that oral antibiotic therapy is equivalent to intravenous antibiotic therapy for the treatment of diabetic foot osteomyelitis.
Interventions
Individuals in this arm receive an intravenous antibacterial agent. They are not assigned to specific medications. Individuals in this arm will receive an intravenous antibacterial agent as determined by their primary healthcare provider. This therapy is usually one of the following intravenous medications: (i) piperacillin/tazobactam (Zosyn), (ii) cefepime, (iii) metronidazole, (iv) aztreonam, (v) vancomycin, (vi) daptomycin, (vii) linezolid (Zyvox), and/or (viii) meropenem.
Individuals in this arm receive an oral antibacterial agent. They are not assigned to specific medications. Individuals in this arm will receive an oral antibacterial agent as determined by their primary healthcare provider. This therapy is usually one of the following oral medications: (i) sulfamethoxazole/trimethoprim (SMX-TMP), (ii) clindamycin (Clindesse), (iii) linezolid (Zyvox), (iv) moxifloxacin (Avelox), (v) ciprofloxacin (Cetraxal), and/or (vi) metronidazole (Flagyl)
Sponsors
Study design
Eligibility
Inclusion criteria
* 18 years of age and older * Diagnosis of Diabetes Mellitus (per past medical history documented in the patient medical record) * Foot osteomyelitis (distal to ankle) * Surgical debridement (in operating room)
Exclusion criteria
* Absolute neutrophil count (ANC) \< 500 * Pregnant or lactating patients * Patients with organisms resistant to oral therapy * Internal hardware * Definitive amputations (BKA) * Limb ischemia \[absent pedal pulses or ankle-brachial index (ABI) \< 0.5\]
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Bone Infection | Six Months | Six months following completion of treatment, the researchers record evidence of bone infection for each participant. A negative diagnosis is made when there is (i) an absence of infection based on clinical examination and (ii) down-trending of inflammatory markers. Otherwise, a positive diagnosis is made. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Ulcer Resolution | Six Months | Six months following completion of treatment, the researchers record whether each participant's ulcer has resolved. |
Countries
United States
Participant flow
Recruitment details
Participants were recruited from March 2014 through February 2017 (36 months) from a tertiary care practice
Pre-assignment details
Prior to randomization, 16 participants were excluded because they tested positive for organisms that were resistant to oral antibiotic therapy. Additionally, one participant withdrew prior to randomization and one participant was excluded prior to randomization due to a definitive amputation.
Participants by arm
| Arm | Count |
|---|---|
| Intravenous Antibacterial Agent Individuals in this arm were randomized to an intravenous antibacterial agent. They were not assigned to specific medications. Instead, individuals in this arm received an intravenous antibacterial agent as determined by their primary healthcare provider. This therapy was usually one of the following intravenous medications: (i) piperacillin/tazobactam (Zosyn), (ii) cefepime, (iii) metronidazole, (iv) aztreonam, (v) vancomycin, (vi) daptomycin, (vii) linezolid (Zyvox), and/or (viii) meropenem. | 7 |
| Oral Antibacterial Agent Individuals in this arm were randomized to an oral antibacterial agent. They were not assigned to specific medications. Instead, individuals in this arm received an oral antibacterial agent as determined by their primary healthcare provider. This therapy was usually one of the following oral medications: (i) sulfamethoxazole/trimethoprim (SMX-TMP), (ii) clindamycin (Clindesse), (iii) linezolid (Zyvox), (iv) moxifloxacin (Avelox), (v) ciprofloxacin (Cetraxal), and/or (vi) metronidazole (Flagyl) | 5 |
| Total | 12 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Lost to Follow-up | 2 | 2 |
Baseline characteristics
| Characteristic | Total | Intravenous Antibacterial Agent | Oral Antibacterial Agent |
|---|---|---|---|
| Age, Continuous | 54.60 years | 56.18 years | 45.86 years |
| Comorbid Cancer No | 12 Participants | 7 Participants | 5 Participants |
| Comorbid Cancer Yes | 0 Participants | 0 Participants | 0 Participants |
| Comorbid Chronic Kidney Disease No | 11 Participants | 7 Participants | 4 Participants |
| Comorbid Chronic Kidney Disease Yes | 1 Participants | 0 Participants | 1 Participants |
| Comorbid Coronary Artery Disease No | 10 Participants | 6 Participants | 4 Participants |
| Comorbid Coronary Artery Disease Yes | 2 Participants | 1 Participants | 1 Participants |
| Comorbid Depression No | 12 Participants | 7 Participants | 5 Participants |
| Comorbid Depression Yes | 0 Participants | 0 Participants | 0 Participants |
| Comorbid Diabetes No | 0 Participants | 0 Participants | 0 Participants |
| Comorbid Diabetes Yes | 12 Participants | 7 Participants | 5 Participants |
| Comorbid Heart Disease No | 11 Participants | 7 Participants | 4 Participants |
| Comorbid Heart Disease Yes | 1 Participants | 0 Participants | 1 Participants |
| Comorbid Hyperlipidemia No | 6 Participants | 3 Participants | 3 Participants |
| Comorbid Hyperlipidemia Yes | 6 Participants | 4 Participants | 2 Participants |
| Comorbid Hypertension No | 4 Participants | 2 Participants | 2 Participants |
| Comorbid Hypertension Yes | 8 Participants | 5 Participants | 3 Participants |
| Comorbid Obesity No | 11 Participants | 6 Participants | 5 Participants |
| Comorbid Obesity Yes | 1 Participants | 1 Participants | 0 Participants |
| Comorbid Peripheral Vascular Disease No | 11 Participants | 6 Participants | 5 Participants |
| Comorbid Peripheral Vascular Disease Yes | 1 Participants | 1 Participants | 0 Participants |
| Comorbid Thyroid Disorder No | 12 Participants | 7 Participants | 5 Participants |
| Comorbid Thyroid Disorder Yes | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 3 Participants | 2 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 9 Participants | 5 Participants | 4 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| History of Heart Attack No | 12 Participants | 7 Participants | 5 Participants |
| History of Heart Attack Yes | 0 Participants | 0 Participants | 0 Participants |
| History of Stroke No | 12 Participants | 7 Participants | 5 Participants |
| History of Stroke Yes | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 3 Participants | 1 Participants | 2 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants | 2 Participants | 0 Participants |
| Race (NIH/OMB) White | 7 Participants | 4 Participants | 3 Participants |
| Region of Enrollment United States | 12 participants | 7 participants | 5 participants |
| Sex: Female, Male Female | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Male | 12 Participants | 7 Participants | 5 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 7 | 0 / 5 |
| other Total, other adverse events | 0 / 7 | 1 / 5 |
| serious Total, serious adverse events | 0 / 7 | 0 / 5 |
Outcome results
Number of Participants With Bone Infection
Six months following completion of treatment, the researchers record evidence of bone infection for each participant. A negative diagnosis is made when there is (i) an absence of infection based on clinical examination and (ii) down-trending of inflammatory markers. Otherwise, a positive diagnosis is made.
Time frame: Six Months
Population: The analysis population comprises all randomized participants who had a six month follow-up appointment.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Intravenous Antibacterial Agent | Number of Participants With Bone Infection | Bone Infection Negative | 5 Participants |
| Intravenous Antibacterial Agent | Number of Participants With Bone Infection | Bone Infection Positive | 0 Participants |
| Oral Antibacterial Agent | Number of Participants With Bone Infection | Bone Infection Negative | 3 Participants |
| Oral Antibacterial Agent | Number of Participants With Bone Infection | Bone Infection Positive | 0 Participants |
Number of Participants With Ulcer Resolution
Six months following completion of treatment, the researchers record whether each participant's ulcer has resolved.
Time frame: Six Months
Population: The analysis population comprises all randomized participants who had a six month follow-up appointment.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Intravenous Antibacterial Agent | Number of Participants With Ulcer Resolution | Resolved | 0 Participants |
| Intravenous Antibacterial Agent | Number of Participants With Ulcer Resolution | Not Resolved | 5 Participants |
| Oral Antibacterial Agent | Number of Participants With Ulcer Resolution | Not Resolved | 2 Participants |
| Oral Antibacterial Agent | Number of Participants With Ulcer Resolution | Resolved | 1 Participants |